SWK HoldingsSWKH
SWKH
About: SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Employees: 22
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 52 [Q3] → 52 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
4.3% less ownership
Funds ownership: 91.85% [Q3] → 87.56% (-4.3%) [Q4]
14% less capital invested
Capital invested by funds: $196M [Q3] → $170M (-$26.7M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SWKH.
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
ImpediMed Secures $15m Growth Capital Funding
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif.
Neutral
Accesswire
1 month ago
SWK Holdings Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024. Originations In November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.
Neutral
Accesswire
3 months ago
SWK Holdings Corporation Announces Financial Results for Third Quarter 2024
Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CST Corporate Highlights Third quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.
Neutral
Accesswire
4 months ago
SWK Holdings Provides Portfolio Update
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule. The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m.
Neutral
Accesswire
6 months ago
SWK Holdings Corporation Announces Financial Results for Second Quarter 2024
Conference Call Scheduled for Friday, August 16, 2024, at 09:00 a.m. CST Corporate Highlights Second quarter 2024 GAAP net income was $4.4 million, compared with net income of $3.9 million for the second quarter 2023 Second quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.5 million, compared with adjusted non-GAAP net income of $7.6 million for the second quarter 2023 As of June 30, 2024, net finance receivables were $265.5 million, a 19.0% increase from June 30, 2023 The second quarter 2024 effective yield was 14.6%, a 10 bps increase from second quarter 2023 As of June 30, 2024, non-GAAP tangible financing book value per share was $20.17, a 6.3% increase from $18.95 at June 30, 2023 DALLAS, TX / ACCESSWIRE / August 15, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the second quarter ended June 30, 2024.
Neutral
Accesswire
7 months ago
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies. "During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs.
Neutral
Seeking Alpha
9 months ago
SWK Holdings Corporation (SWKH) Q1 2024 Earnings Call Transcript
SWK Holdings Corporation (NASDAQ:SWKH ) Q1 2024 Results Conference Call May 16, 2024 10:00 AM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Jody Staggs - President and Chief Executive Officer Conference Call Participants Mark Argentino - Lake Street Operator Good morning, everyone, and welcome to the SWK Holdings First Quarter 2024 Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.
Neutral
Accesswire
9 months ago
SWK Holdings Corporation Announces Financial Results for First Quarter 2024
Conference Call and Live Audio Webcast Scheduled for Thursday, May 16, 2024, at 10:00 a.m. ET Corporate Highlights First quarter 2024 GAAP net income was $0.9 million, compared with net income of $4.6 million or $0.36 per share, for the first quarter 2023 First quarter 2024 finance receivables segment adjusted non-GAAP net income was $2.7 million, compared with adjusted non-GAAP net income of $7.3 million for the first quarter 2023 As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase from March 31, 2023 As of March 31, 2024, book value per share was $22.46 As of March 31, 2024, non-GAAP tangible financing book value per share was $19.69 First quarter 2024 finance portfolio effective yield was 14.2%, a 130-basis-point decrease from March 31, 2023 During first quarter 2024, Enteris signed the Option and Asset Purchase Agreement with a strategic partner and Enteris received the first low-single digit million option fee in April 2024 SWK repurchased 58,298 shares of common stock during the first quarter 2024 for a total cost of approximately $1.0 million DALLAS, TX / ACCESSWIRE / May 15, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the first quarter ended March 31, 2024.
Neutral
Accesswire
11 months ago
SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2023
Conference Call and Live Audio Webcast Scheduled for Thursday, March 21, 2024, at 10:00 a.m. ET Corporate Highlights Fourth quarter 2023 and 2022 net income was $2.8 million Full year 2023 net income was $15.9 million, compared to full year 2022 net income of $13.5 million Closed a $33.0 million public offering of senior notes Repurchased 14,233 shares of common stock during the fourth quarter for a total cost of $0.2 million; year-to-date 2024 through March 14th, repurchased an additional 51,169 shares for a total cost of $0.9 million After quarter end, signed Exclusive Option and Asset Purchase Agreement granting strategic partner an exclusive two-year option to purchase certain tangible assets of Enteris for approximately $6 million, in exchange for a low-single digit million dollar option fee as well as mid-single digit million dollar guaranteed annual revenue payments in calendar years 2024 and 2025 Finance Receivables Segment Update Fourth quarter 2023 finance receivables segment adjusted non-GAAP net income was $3.7 million, compared with segment adjusted non-GAAP net income of $4.4 million for the fourth quarter of 2022 For 2023, the specialty finance segment generated a 10.0% adjusted return on tangible book value As of December 31, 2023, gross finance receivables were $288.4 million, a 16.1% increase from December 31, 2022 During the fourth quarter 2023, closed four new financing transactions totaling $55.1 million including a $20.0 million loan to Shield Therapeutics PLC, a $6.0 million loan to Nicoya Lifesciences, Inc., a $15.0 million loan to Journey Medical Corporation, and the $14.1 million purchase of a series of sales-based milestones on a portfolio of Immune Globulin products Fourth quarter 2023 finance portfolio effective yield was 14.0%, a 10-basis-point increase from December 31, 2022 Fourth quarter 2023 finance portfolio realized yield was 14.1%, a 310-basis-point increase from December 31, 2022 As of December 31, 2023, book value per share was $22.43 and non-GAAP tangible financing book value per share was $19.61 DALLAS, TX / ACCESSWIRE / March 21, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2023.
Neutral
Accesswire
1 year ago
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / January 23, 2024 / SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. "We concluded 2023 with a surge in deal activity as the 2023 investments SWK has made in the team and underwriting process paid dividends through an increased pipeline and four deal closings," stated Jody Staggs, President and CEO of SWK.
Charts implemented using Lightweight Charts™